Kelly D Flemming1. 1. Department of Neurology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN, 55905, USA. Flemming.Kelly@mayo.edu.
Abstract
PURPOSE OF REVIEW: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). RECENT FINDINGS: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.
PURPOSE OF REVIEW: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). RECENT FINDINGS:Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.
Authors: D Rigamonti; M N Hadley; B P Drayer; P C Johnson; K Hoenig-Rigamonti; J T Knight; R F Spetzler Journal: N Engl J Med Date: 1988-08-11 Impact factor: 91.245
Authors: Jeremy K Cutsforth-Gregory; Giuseppe Lanzino; Michael J Link; Robert D Brown; Kelly D Flemming Journal: J Neurosurg Date: 2015-02-20 Impact factor: 5.115
Authors: D Jay McCracken; Jon T Willie; Brad A Fernald; Amit M Saindane; Daniel L Drane; Daniel L Barrow; Robert E Gross Journal: Oper Neurosurg (Hagerstown) Date: 2015-09-25 Impact factor: 2.703
Authors: J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown Journal: J Neurosurg Date: 1994-03 Impact factor: 5.115
Authors: Robert Shenkar; Changbin Shi; Douglas A Marchuk; Issam A Awad; Tania Rebeiz; Rebecca A Stockton; David A McDonald; Abdul Ghani Mikati; Lingjiao Zhang; Cecilia Austin; Amy L Akers; Carol J Gallione; Autumn Rorrer; Murat Gunel; Wang Min; Jorge Marcondes De Souza; Connie Lee Journal: Genet Med Date: 2014-08-14 Impact factor: 8.822
Authors: Hyun Ah Kim; Andrea Perrelli; Alberto Ragni; Francesca Retta; T Michael De Silva; Christopher G Sobey; Saverio Francesco Retta Journal: Antioxidants (Basel) Date: 2020-04-17
Authors: Andrea Perrelli; Luca Goitre; Anna Maria Salzano; Andrea Moglia; Andrea Scaloni; Saverio Francesco Retta Journal: Oxid Med Cell Longev Date: 2018-08-23 Impact factor: 6.543